

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 8/2023

Date of preparation: 2023-04-26

Abbreviated name of the Issuer: MABION S.A.

Subject matter:

Decision to close the patent procedures for MabionMS

Legal basis:

Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Reports no. 56/2017 of 5 December 2017, no. 59/2018 of 26 October 2018, and no. 61/2018 of 5 December 2018 concerning the patent applications submitted for the inventions entitled "Combination Therapy of Multiple Sclerosis comprising a CD20 Ligand" and "Low aggregate anti CD20 ligand formulation", developed as part of the MabionMS (MS, multiple sclerosis) project of innovative therapy, the Management Board of Mabion S.A. "Issuer", "Company" hereby informs that today, it has decided to discontinue its efforts to obtain patent protection under the above-mentioned applications.

The Management Board's decision is based on the implementation of Mabion S.A.'s Strategy for 2023-2027 of whose adoption the Issuer informed in Current Report no. 7/2023 of 18 April 2023.

Pursuant to the Company's Strategy for 2023-2027, the Company plans to further its transformation into a fully integrated CDMO ("Contract Development and Manufacturing Organisation") focused on biologics.

Analogous decisions have been taken with respect to all patent applications as part of the MabionMS project, of which the Company informed in interim reports, including most recently in the annual report for 2021 published on 21 April 2022.